Dual-subtype FIV vaccine (Fel-O-Vax® FIV) protection against a heterologous subtype B FIV isolate

@article{Pu2005DualsubtypeFV,
  title={Dual-subtype FIV vaccine (Fel-O-Vax{\textregistered} FIV) protection against a heterologous subtype B FIV isolate},
  author={Ruiyu Pu and James K. Coleman and James G Coisman and Eiji Sato and Taishi Tanabe and Maki Arai and Janet K. Yamamoto},
  journal={Journal of Feline Medicine and Surgery},
  year={2005},
  volume={7},
  pages={65 - 70}
}
View on SAGE
ncbi.nlm.nih.gov
57 Citations
Highly Influential Citations
2
Background Citations
16
Methods Citations
4
Results Citations
1

Figures from this paper

57 Citations

Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge

Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies: Efficacy and potential prophylactic mechanism(s) of prototype and commercial FIV vaccines

This is the first large-scale study characterizing shortand long-duration efficacies of dual-subtype FIV vaccines against heterologous subtype and recombinant viruses, as well as FIV tiers based on in vitro NAb analysis and in vivo passive-transfer studies, and demonstrates that not all vaccine protection is mediated by vaccine-induced NAbs.

Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Findings from these studies are being used to define the prophylactic epitopes needed for an HIV-1 vaccine for humans.

Vaccine protection against feline immunodeficiency virus: setting the challenge.

The challenges facing vaccine development, the current state of knowledge and future prospects for FIV vaccination are reviewed.

Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency virus vaccine (Fel-O-Vax FIV) inoculated cats.

An updated nation-wide epidemiological survey of feline immunodeficiency virus (FIV) infection in Japan.

An updated nation-wide epidemiological survey of feline immunodeficiency virus (FIV) infection was conducted in Japan and a geographic distribution of four subtypes (A, B, C and D) of FIV in Japan was disclosed.

Limited efficacy of an inactivated feline immunodeficiency virus vaccine

The vaccine is licensed in the USA, Canada and Australia for use in cats over eight weeks of age, and has been shown to provide protection against a number of FIV isolates, including those of subtypes A, B and C.

Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine.

This data indicates that FIV infection in cats is a natural infection of domestic felid populations which results in a chronic and progressive acquired immunodeficiency syndrome and that vaccination against FIV is a viable treatment option for these patients.

Sequence variation of the feline immunodeficiency virus genome and its clinical relevance

It is important that the key determinants of immunity induced by this vaccine are discovered; such data would compliment vaccine field efficacy studies and provide the basis to make informed recommendations on its use.

The protective rate of the feline immunodeficiency virus vaccine: An Australian field study.

...

References

SHOWING 1-10 OF 20 REFERENCES

Vaccination of cats against feline immunodeficiency virus (FIV): a matter of challenge.

Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates

Dual-subtype vaccinated cats developed broad-spectrum humoral and cellular immunity which protected cats against in vivo-derived inocula of homologous and heterologous FIV subtypes, suggesting an increase in cytotoxic cell activities against AIDS viruses.

Perspectives on FIV vaccine development.

FIV vaccine development and its importance to veterinary and human medicine: a review

Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.

Vaccination with experimental feline immunodeficiency virus vaccines, based on autologous infected cells, elicits enhancement of homologous challenge infection.

The results of the present study are discussed in the light of enhancement of lentiv virus infections as a complicating factor in lentivirus vaccine development.

Enhancement after feline immunodeficiency virus vaccination.

Vaccination with Inactivated Virus but Not Viral DNA Reduces Virus Load following Challenge with a Heterologous and Virulent Isolate of Feline Immunodeficiency Virus

Results indicate that the more virulent FIVGL8 is intrinsically more resistant to vaccinal immunity than the FIVPET strain and that a broad spectrum of responses which includes virus neutralizing antibodies is a desirable goal for lentivirus vaccine development.

Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades

Analysis of all available FIV env sequences revealed the existence of recombinant viruses generated from subtype A/B, B/D, and A/C envelope gene sequences, consistent with the hypothesis that Fiv-B is an older virus group and is possibly more host adapted than FIV-A.

MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.

Protection mediated by adoptive transfer of immunocytes from vaccinated cats was MHC-restricted, occurred in the absence of antiviral humoral immunity, and correlated with the transfer of cells with FIV-specific CTL and T-helper activities.